Business
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering,
About this update from Century Therapeutics, Inc.
[{"type":"text","content":"Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology\nPHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA. The upcoming abstracts highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, protein engineering and computational biology. Additionally, the Company will share new preclinical data on additional Allo-Evasion™ edits that could further support Century’s multi-dosing strategy. Details of the poster presentations are as follows: Abstract Number: 36Title: The Discovery of A Novel CD19xCD22 Dual-Targeting CAR For The Development Of An iPSC-Derived Cell Therapy Poster Board Number: 4Session Title: Adoptive Cell Therapies 2: CAR-T CellsSession Date: Sunday, April 7, 2024Session Time: 1:30 PM - 5:00 PM PT Abstract Number: 1320Title: Engineered Expression Of HLA-E And HLA-G Protects iPSC-Derived Cells from Killing By Primary NK Cells Poster Board Number: 3Session Title: CAR-K, NK Engagers, and NK ModulatorsSession Date: Monday, April 8, 2024 Session Time: 9:00 AM - 12:30 PM PT Abstract Number: 3613Title: Screening iPSC Lines for Optimal Characteristics of Differentiation into Immune Effector Cells for Clinical Programs Poster Board Number: 19Session Title: Adoptive Cellular Therapy 1Session Date: Monday, April 8, 2024 Session Time: 1:30 PM - 5:00 PM PT Abstract Number: 1916Title: Discovery of a Novel Nectin4 iPSC-derived Cell Therapy for the Treatment of Solid Tumors Poster Board Number: 27Session Title: Antibody Drug Conjugates and Bispecific AntibodiesSession Date: Monday, April 8, 2024Session Time: 9:00 AM - 12:30 PM PT Abstract Number: 4009Title: Discovery Of Inhibitory CAR Target DSG1 For Damping NECTIN4 On-Target Off-Tumor Toxicity in iPSC-Derived CAR-T Cell Therapy Poster Board Nu...